Traws Pharma, Inc. (TRAW): M&A transaction — Traws Pharma acquires antiviral compound assets from Viriom for $2.35M cash

Traws Pharma, Inc.

Acquired IP and assets for pyrrolidine antiviral compound from Viriom for $2,350,000 cash paid on September 9, 2025.
Nikolay Savchuk, Traws COO, is Executive Chairman of Viriom; Dr. Robert Redfield, Traws CMO, on Viriom board; related-party transaction approved by audit committee.
Assets include patents, license agreements, regulatory filings, and materials exclusively related to the compound and program.

item 1.01 item 2.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Traws Pharma, Inc. completed an acquisition involving Virom, Inc. for $2,350,000 in cash (closed 2025-09-09).

Action: acquisition
Counterparty: Virom, Inc.
Consideration: $2,350,000 in cash
Closing: 2025-09-09

Exact text from the filing

On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025.

View on SEC.gov

Browse all m&a transactions →

Traws Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-089564

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.